-
Synaptogenix (SNPX) Announces $5.0 Million Financing
-
Synaptogenix (SNPX) Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
-
Synaptogenix (SNPX) Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1

